Scholar Rock Raises Price Target to $97 on Strong Phase 3 Data, Manages FDA Manufacturing Hurdles
Analyst raises Scholar Rock price target to $97, citing apitegromab’s Phase 3 topline data and broad label potential that could expand its addressable market. FDA manufacturing delays are non‐clinical with remediation underway and a second CDMO engaged, leaving approval timeline and commercial rollout prospects intact.
1. Analyst Price Targets and Ratings
On January 7, 2026, UBS analyst Michael Yee set a 12-month price target of $60 for Scholar Rock Holding Corporation, implying upside of roughly 45%. Barclays followed suit, raising its own target from $45 to $52 while maintaining an “overweight” rating. Wolfe Research initiated coverage on November 18 with an “outperform” rating and a target of $42, and Cantor Fitzgerald reiterated its “overweight” view on December 11. Collectively, these forecasts drive the consensus 12-month target to $48.90.
2. Consensus Recommendation and Broker Breakdown
Among sixteen reporting brokerages covering Scholar Rock, eleven carry a “buy” recommendation, four rate the shares as “strong buy” and one issues a “sell” rating. This distribution underpins a consolidated “Buy” consensus, reflecting broad confidence in the company’s pipeline progress and commercial prospects for its lead asset, apitegromab.
3. Recent Trading Activity and Market Metrics
Despite a pullback of 3.39% in recent sessions, SRRK shares have traded in a narrow intraday band of $41.19 to $43.06. Over the past 52 weeks the stock peaked at $48.28 and troughed at $22.71. Market capitalization stands at approximately $4.21 billion, with average daily volume around 707,076 shares, signaling sustained investor engagement in the biopharma name.